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Proteomic Proﬁling of Mouse Helper T Cell Diﬀerentiation
Henk-Jan van den Ham,* Nadine A. Binai, Fatiha Zaaraoui-Boutahar, Albert J. R. Heck,
and Arno C. Andeweg
Helper T cell diﬀerentiation is a key process in the regulation of adaptive
immune responses. Here, mouse Th1 and Th2 cells are proﬁled using
high-throughput proteomics to increase the understanding of the molecular
biology of Th diﬀerentiation to support the design of prophylactic and
therapeutic intervention strategies for (infectious) diseases. Protein proﬁling
of Th1/Th2 diﬀerentiated cells results in the quantiﬁcation of almost 6000
proteins of which 41 are diﬀerentially expressed at FDR < 0.1, and 19 at the
FDR < 0.05 level, respectively. Diﬀerential protein expression analysis
identiﬁes a number of the expected canonical Th diﬀerentiation markers, and
gene set analysis using the REACTOME database and a hypergeometric test
(FDR < 0.05) conﬁrms that helper T cell pathways are the top sets that are
diﬀerentially expressed. Additionally, by network analysis, many diﬀerentially
expressed proteins are associated with the Th1 and Th2 pathways. Data are
available via PRIDE database with identiﬁer PXD004532.
The adaptive immune response is of key importance in protect-
ing a host from pathogens. Helper T (Th) cells play a pivotal
role in regulating this response. The role of CD4+ Th cells is
to coordinate the activity of other immune cells by the produc-
tion and release of cytokines, including the induction of class
switching in B cells, activation and proliferation of cytotoxic T-
cells, and, for instance, activation of macrophages. Th cells have
the ability to diﬀerentiate into several distinct subtypes, of which
Th1 and Th2 are best understood. By releasing the inﬂammatory
cytokine IFN-γ , Th1 cells support cellular eﬀector mechanisms
that counter intracellular pathogens. Th2 cells promote humoral
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responses that are antibody-based
responses mostly directed against extra-
cellular pathogens, but also to allergens
and toxins.[1] Inducing the appropri-
ate Th driven immune phenotype is
crucial as the inappropriate or ‘wrong’
phenotypic response may be ineﬀective
and may even lead to severe immune-
pathology.[2] Understanding of the
molecular mechanisms of Th diﬀerenti-
ation will contribute to the development
of better vaccines to combat infec-
tious diseases, as well as to improved
therapies against autoimmune and
other immune-mediated diseases.[1–5]
In the past few decades, high-
throughput technology has been used
to discern the precise molecular details
of helper T cell diﬀerentiation. These
studies have been performed in both human as well as mouse
cells; Th1 and Th2 cells have been discovered in mouse models,
and mice have since remained an important model system for
Th cell diﬀerentiation. A range of studies have investigated the
transcriptomes of Th cells for both human and mouse Th,[6–9]
using both in vitro and in vivo approaches. Early attempts in pro-
ﬁling the proteome of human Th1 and Th2 cells revealed very few
proteins being diﬀerentially regulated between Th1 and Th2.[10]
Moulder et al. focused their investigation on the nuclear fraction
of Th2 cells unravelling the involvement of novel proteins like
SATAB1.[11] However, very few studies have been performed in
mouse Th cells. A recent study investigated the diﬀerentiation of
T cells to Th17 and iTreg subsets[12] providing a valuable resource
for further characterization of these cell types. In this study, we
set out to perform comprehensive proteome proﬁling of mouse
Th1 and Th2 cells.
In order to access the diﬀerences in protein expression in pri-
mary mouse Th1 and Th2 cells, we designed the following exper-
iment: CD4+ cells were isolated from the spleens of 32 C57Bl/6
mice and ex vivo stimulated to diﬀerentiate into Th1, Th2, or Th0
(neutral) cells. The spleens were divided into four groups and
were homogenized using 100 µm Cell Strainers (Falcon) in Op-
Timizer CTS medium (Gibco A10221-01) as four separate pools
to obtain four biological replicates for every treatment. This step
was necessary to obtain enough material and helps to remove
inter-individual variability. Every sample consisted of 6M cells,
cultured in 96-well plates at a density of 250 000 cells per well.
Red blood cells were removed using RBC lysis buﬀer (Roche Di-
agnostics GmbH 11814389001). CD4+ T cells were isolated us-
ing a MACS CD4+ Cell Isolation Kit II (mouse, Miltenyi Biotech
130-095-248). Cells were activated using Dynabeads Mouse
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Figure 1. A) Setup of the experiment. Cells were isolated from mouse spleens, homogenized, activated, and processed to isolate proteins. The protein
samples were digested, labeled, and mixed, and the resulting peptide mixtures were fractionated by strong-cation exchange (SCX) chromatography, and
eventually measured using RP-LC–MS/MS. B) Mixing scheme for the three-plex dimethyl labeling. R1–R4 indicate biological replicate experiments.
T-Activator CD3/CD28 (Gibco, 11452D) andwere cultured inOp-
Timizer medium supplemented with 10 ng mL–1 murine IL-2
(PeproTech Inc.; catalog number 212-12, A2313) in 96-well plates
(250 000 cells per well). CD4+ cells were skewed toward Th1
by adding in 25 ng mL–1 IL-12 (PeproTech Inc.; catalog number
210–12, G2111) and 1 µg mL–1 αIL-4 antibody (FGP anti-mouse
IL4, clone 11B11, dat# 16-7041-85) to the culture medium. CD4+
cells were skewed toward Th2 by adding 10 ng mL–1 IL-4 (Pepro-
Tech Inc.; catalog number 214-14, F2613) and 1 µg mL–1 αIFN-γ
antibody (FGP antimouse IFN-γ , clone XMG1.2, catalog number
16-7311-81) to the culture medium. No skewing cytokines were
added to the “neutral” stimulated Th0 cells (Figure 1).
The diﬀerentiation into Th1 and Th2 phenotypes can already
be detected within 1 day post-activation at themRNA level.[6,8] For
proteome analysis, we allowed the cells for full phenotype devel-
opment for 3 days. In order to evaluate successful diﬀerentiation
at the mRNA level, we collected RNA at day 3 and measured the
expression of Th cell marker genes Tbx21 (Tbet), Ifng (IFN-γ ),
Gata3, and Il4. Cells were harvested and immediately collected
in TRIzol, and processed as described before.[6] Brieﬂy, total RNA
was isolated, puriﬁed, and transcribed into cDNA. Expression of
the key transcription factor and cytokine marker genes was veri-
ﬁed using qRT-PCR.[6] qRT-PCR values were normalized against
β-actin mRNA expression levels using the –Ct method as
done in ref. 13. As expected, Tbet and IFN-γ are upregulated
in Th1 cells, but not in Th2 cells; conversely, Gata3 and IL-4 are
upregulated in Th2 and downregulated in Th1 (Figure S1, Sup-
porting Information). This shows that the diﬀerentiation of cells
was successful and that we are proﬁling “bona ﬁde” Th1 and Th2
cell cultures.
Protein proﬁling was performed as described before[14,15] and
detailed methods are provided in the Supporting Information.
Brieﬂy, from a third part of each sample, we created a pool that
was labeled with a “light” stable isotope dimethyl label and used
in each run mix as a common reference. Two individual repli-
cate samples were chemically labeled with either “medium” or
“heavy” stable isotope dimethyl labels and subsequently com-
bined with a “light”-labeled pool sample aliquot resulting in six
mixtures for each of the six runs. By swapping the medium
and heavy label between biological replicates, labeling eﬃciency
bias was avoided (Figure 1B). Labeling eﬃciency was >95%
(data not shown). Analysis of prefractionated peptidemixtures by
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Figure 2. Diﬀerential protein expression for the Th2 versus Th1 contrast, with average log2-fold change plotted on the x-axis and log odds value (B-
statistic) plotted on the y-axis. Signiﬁcantly changing protein expression values are shown in light red (FDR < 0.1) and dark red (FDR < 0.05). Venn
diagrams for all contrasts are given as inset.
RP-LC–MS/MS resulted in the identiﬁcation of about 6000 pro-
teins in the individual mixes (Figure S2A, Supporting Informa-
tion) and 7410 proteins in all run mixes combined. We could
quantify over 90% (6601) of the identiﬁed proteins. The identiﬁed
proteins cover all cellular compartments (Figure S2B, Supporting
Information) ensuring a representative view on the proteome of
these cells.
In order to identify proteins that are diﬀerentially expressed
between the Th1, Th2, and/or neutral phenotypes, we performed
diﬀerential protein expression analysis using limma (version
3.20.8, Bioconductor Biobase 2.24.0, R 3.1.3) on nonimputed pro-
tein data. The mouse/spleen group from which the cells were
derived was used as a co-variate to control for replicate associ-
ated eﬀects, for details see refs. 16 and 17. The intensity data
was processed using custom R scripts: after log2-transformation,
the sample medians were shifted onto a single median value
(Figure S3, Supporting Information). To determine protein in-
tensity values, the peptide intensities were rolled up using me-
dian polish (R 3.1.3, base package stats, function medpolish).We
compared all groups to one another, and we observed that the
Th2–Th1 comparison yields 41 diﬀerentially expressed proteins
at FDR < 0.1 (Figure 2, inset), and 19 at the FDR < 0.05 level
(Figure 2, red dots). No proteins were found to change expres-
sion in the Th1–Th0 contrast. All of the diﬀerentially expressed
proteins identiﬁed in the Th2–Th0 contrast (eight for FDR< 0.1,
Figure 2, inset) are also identiﬁed in the Th2–Th1 comparison.
We show the latter contrast using a volcano plot that depicts
log2-fold change versus signiﬁcance of diﬀerential expression
(log odds, Figure 2). There are relatively few signiﬁcant changes
in the proteome between the diﬀerent cell phenotypes. Pearson
correlation analysis of all samples revealed weak to moderate
correlation (0.4–0.8) of the individual samples with each other
(Figure S4, Supporting Information). Thismight be related to the
small fraction of diﬀerentially regulated proteins that are associ-
ated with cell diﬀerentiation. We performed over-representation
analysis on the signiﬁcant proteins of the Th2–Th1 contrast (FDR
< 0.1) using REACTOME.[18] When applying a FDR < 0.05
threshold to the results of the gene set analysis, we found four
pathways in cytokine signaling: IL4 and IL13 signaling, IFN sig-
naling, and IL-6 signaling (Table S1, Supporting Information).
These are pathways we expect to be diﬀerentially expressed as
they are the direct result of cytokine signaling in T cells.
To further investigate functional relationships of the proteins
that are diﬀerentially expressed, we constructed protein–protein
interaction networks using our results (Figure 2) and the RE-
ACTOME FI PlugIn in Cytoscape v3.2. The REACTOME Func-
tional Interaction network is a highly reliable, manually curated
pathway-based protein functional interaction network. When all
diﬀerentially expressed proteins are used to create a network,
we could connect nine out of the 41 most signiﬁcant proteins
(Figure 3A). The transcriptional regulator Stat1 that activates
transcription of the Th1 cell master regulator T-bet (TBX21)[19]
is positioned in the center of this network. The antiviral pro-
tein Bst2 is also a direct interactor of the IFN-γ /Stat1 pathway
(Figure 3A) and was found in an early proteomics study as be-
ing more abundant on the surface of Th1 cells.[20] If we add six
non-observed proteins to extend the Th1 network,many other ob-
served Th1-related proteins become connected (Figure 3B). The
tyrosine kinase TXKmay potentiate IFN-γ signaling.[21] The tyro-
sine phosphatase PTPN12 is known as positive regulator of sec-
ondary T cell activation, but also prevents anergy and induction
of autoimmunity.[22] For the other proteins in the network, a con-
nection to the Th1 phenotype is less obvious. Furthermore, we
can link 14 out of the 18 proteins that show higher abundance in
Th2 into another network by adding only seven linker proteins
(Figure 3C). The cytokine IL-4 drives Th2 diﬀerentiation. After
recognition by its receptor a signaling cascade involving Jak2 and
Stat6 is activated, leading to the expression of the master regula-
tor GATA3. We found the IL-4 receptor to be upregulated in Th2
cells as well as Jak2 that transmits the signal from the receptor
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Figure 3. Network analysis of signiﬁcantly (FDR < 0.1) changing proteins. A) Network of all signiﬁcantly changing proteins that could be mapped. The
color-coding indicates the fold change in the comparison Th1 versus Th2. The darker the color the stronger the fold change. B) Reactome network of Th1
speciﬁc proteins (green circles) supplemented with linkers (grey diamonds). C) Reactome network of Th2 speciﬁc proteins (purple circles) supplemented
with linkers (grey diamonds). The connections between the proteins indicate their relationship to each other “→” for activating/catalyzing, “-|” for
inhibition, “-” for functional interactions extracted from complexes or inputs, and “—” for predicted functional interactions.
to Stat6. However, IL4 can also activate PI3K signaling pathway
via Janus kinases. Furthermore, this pathway activates the adap-
tor protein GRAP, a negative regulator of the Erk signaling.[23]
With Dok2, we identiﬁed another adaptor protein that may neg-
atively regulated TCR signaling.[24] Also tyrosine kinase CSK is a
negative regulator of TCR signaling. It phosphorylates inhibitory
residues on Src-family kinases.[25] In conclusion, many of the
diﬀerentially expressed proteins have a well-documented role in
Th1–Th2 diﬀerentiation (Table S2, Supporting Information); for
others, no clear role has been described.
In this study, we have proﬁled neutral, Th1, and Th2 cells that
were induced by skewing primary naive Th cells derived from
mouse spleens. Our diﬀerential protein analysis shows that, as
expected, cytokine signaling is one of the main molecular path-
ways that are activated. Transcription factor Tbet (TBX21), the
Th1 master regulator, is signiﬁcantly upregulated in Th1 com-
pared to Th2 cells. Even though the Th2 signature transcription
factor GATA3 does not emerge as signiﬁcantly regulated at the
protein level, we could detect diﬀerential protein expression of
upstream members of the GATA3 induction pathway, such as
IL4R and Jak2. They are known to activate the transcription factor
Stat6, which drives GATA3 transcription. Furthermore, we could
show diﬀerential expression of many genes at the protein level
previously linked to Th skewing in mRNA proﬁling studies. For
instance, we suggested that RBPJ is involved in the regulation of
the Th2-like Th9 phenotype,[26] and that Batf is involved in Th2
skewing.[6] This indicates that we have indeed identiﬁed some of
themajor protein players in Th1/Th2 diﬀerentiation in our study.
Despite the successful quantiﬁcation of 6600 annotated proteins,
only a small number of diﬀerentially expressed proteins linked to
Th diﬀerentiation could be identiﬁed. This may be due to run-to-
run variability in the assay. Consequently, the proteins that are de-
tected diﬀer from run to run, resulting inmissing quantiﬁcations
in the (replicate values of the) data set. Although these can be im-
puted, we recently showed that this leads to high levels of false
positives and hence, is not recommended for high-throughput
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protein analysis.[16] Future proteomics experiments will yield ad-
ditional proteins involved in Th skewing, but the observation that
only a small fraction of all (quantiﬁed) proteins are associated
with Th diﬀerentiation is in line with our genome wide mRNA
proﬁling experiments. These experiments also showed that only
a relative small fraction (hundreds of genes) of all genes is dif-
ferentially regulated in similar Th skewing conditions (6). The
currently identiﬁed set of proteins associated with Th skewing
appears “bona ﬁde” hits, which is conﬁrmed by the large overlap
obtained with our earlier mRNA results.[6] The presently identi-
ﬁed proteins will support future research on the biology of Th
diﬀerentiation.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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